RxDoctor Payments Data

Marwan Mustaklem

Internal Medicine · Indianapolis, INNPI 1750357513

Payments from drug & device makers

$3,490in general payments, 2019–2025

Across 14 payments — averaging $249.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Sun Pharmaceutical Industries Inc.$120
  • AbbVie$44
  • Novo Nordisk$26
  • Pfizer$22
  • Neurocrine Biosciences, Inc.$17

What the payments were for

  • Consulting fees$3,15090%
  • Travel & lodging$341%
  • Food & beverage$3069%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,490 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$765,289
Medicare patients
1,812
Services billed
11,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban3,586$1,221,871
JardianceEmpagliflozin600$207,753
Invega SustennaPaliperidone Palmitate71$206,021
TrulicityDulaglutide260$189,391
XareltoRivaroxaban541$189,361
JanuviaSitagliptin Phosphate401$138,861
MyrbetriqMirabegron447$122,826
EntrestoSacubitril/Valsartan324$118,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter193$110,718
Humira(Cf) PenAdalimumab13$94,559
TriumeqAbacavir/Dolutegravir/Lamivudi20$79,403
IngrezzaValbenazine Tosylate20$73,618
OzempicSemaglutide71$72,268
Risperdal ConstaRisperidone Microspheres29$69,714
Breo ElliptaFluticasone/Vilanterol156$68,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$1,221,8713,586 claims
Lilly USA, LLCTrulicity, Mounjaro$3,261$256,096336 claims
AbbVieLinzess, Creon$44$104,093148 claims
Neurocrine Biosciences, Inc.Ingrezza$17$73,61820 claims
Novo NordiskOzempic$26$72,26871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →